GW Pharmaceuticals (GWP) - GW to Present at Lazard Healthcare Conference RNS Number : 8253Q GW Pharmaceuticals PLC 12 November 2012 GW Pharmaceuticalsto Present at Lazard Healthcare Conference in New York Porton Down, UK; 12 November 2012: GW Pharmaceuticals plc (AIM: GWP) today announces that itsManaging Director,Justin Gover will be presenting at theLazard Capital Markets 9^th Annual Healthcare Conference inNew York onTuesday, 13 November 2012 at11.30am EST (4.30pmGMT). A live webcast will be accessible via the investor relations section of the GW website. -ends- Enquiries: GW Pharmaceuticals plc (Today) + 44 20 7831 3113 Dr Geoffrey Guy, Chairman (Thereafter) + 44 1980 557000 Justin Gover, Managing Director FTI Consulting + 44 20 7831 3113 Ben Atwell / John Dineen / Simon Conway Peel Hunt LLP +44 (0)20 7418 8900 James Steel / Vijay Barathan Note to Editors About GW GW was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For further information, please visit www.gwpharm.com This information is provided by RNS The company news service from the London Stock Exchange END NRAFSLFWUFESEDF -0- Nov/12/2012 07:01 GMT
GW Pharmaceuticals GWP GW to Present at Lazard Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.